ORIFARM GENERICS A/S: Financial statements 2018
CVR: 25674030
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 504,442,000 and a net result of DKK 70,055,000 compared with DKK 76,351,000 the year before. The profit margin was 13.9%. Equity in the 2018 report amounted to DKK 116,825,000. The solvency ratio was 39.6%. The company had 102 employees in the financial year.
- Revenue
- DKK 504,442,000
- Gross Profit
- DKK 162,693,000
- Profit/Loss
- DKK 70,055,000
- Equity
- DKK 116,825,000
- Total Assets
- DKK 295,017,000
- Employees
- 102
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 504.4 mio. | 162.7 mio. | 70.1 mio. | 116.8 mio. | 102 |
| 2017 | - | 172 mio. | 76.4 mio. | 86.8 mio. | 97 |
| 2016 | - | 169.9 mio. | 83.3 mio. | 60.4 mio. | 78 |
| 2015 | - | 40 mio. | 605 t. | 8 mio. | - |
| 2014 | - | 32.1 mio. | 550 t. | 7.4 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
ORIFARM GENERICS A/S has published its annual report for 2017. Gross profit came to DKK 171,953,000, and the net result was DKK 76,351,000.
As of May 15, 2018, Karsten Haumann is registered as adm. dir. of ORIFARM GENERICS A/S.
As of May 15, 2018, Ulrik Ernst Rasmussen has stepped down as adm. dir. of ORIFARM GENERICS A/S.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.